Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Charles River Laboratories International's current 3-Month Share Buyback Ratio was 2.13%.
Charles River Laboratories International (NYSE:CRL) 3-Month Share Buyback Ratio Explanation
A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Charles River Laboratories International 3-Month Share Buyback Ratio Related Terms
CRL vs RVTY, ICLR, QGEN: 3-Month Share Buyback Ratio Comparison
For the Diagnostics & Research subindustry, Charles River Laboratories International's 3-Month Share Buyback Ratio, along with its competitors' market caps and 3-Month Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Charles River Laboratories International 3-Month Share Buyback Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Charles River Laboratories International's 3-Month Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Charles River Laboratories International's 3-Month Share Buyback Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 3-Month Share Buyback Ratio of 2.13 mean?
Charles River Laboratories International (CRL) has a 3-Month Share Buyback Ratio of 2.13 as of Mar. 2026. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Charles River Laboratories International and its competitors.
Is Charles River Laboratories International's 3-Month Share Buyback Ratio too high?
Charles River Laboratories International's current 3-Month Share Buyback Ratio is 2.13. Overall, Charles River Laboratories International has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Charles River Laboratories International's 3-Month Share Buyback Ratio compare to RVTY and ICLR?
Charles River Laboratories International's 3-Month Share Buyback Ratio of 2.13 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Medical Diagnostics & Research company?
A good 3-Month Share Buyback Ratio depends on the Medical Diagnostics & Research industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Charles River Laboratories International and its competitors. Charles River Laboratories International's current 3-Month Share Buyback Ratio is 2.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Charles River Laboratories International stock overvalued right now?
Based on GuruFocus' analysis, Charles River Laboratories International (CRL) is currently considered Modestly Overvalued. The stock's GF Value™ is $193.73, compared to a current price of $232.51 — trading 20% above its estimated fair value. The current 3-Month Share Buyback Ratio is 2.13. Charles River Laboratories International's overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For Charles River Laboratories International (CRL), the current 3-Month Share Buyback Ratio is 2.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Charles River Laboratories International (CRL) Overvalued in 2026?
Based on GuruFocus' analysis, Charles River Laboratories International stock appears to be overvalued.
The current stock price of $232.51 is trading 20% above its estimated GF Value™ of $193.73.
GuruFocus considers Charles River Laboratories International to be Modestly Overvalued.
Key valuation signals for CRL:
3-Month Share Buyback Ratio: 2.13
GF Value™: $193.73 vs. price of $232.51 (20% above fair value)
No single metric tells the full story. See the CRL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
71GF Score
Get the complete analysis for CRL
3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRL has been successfully added to your 
